LSD1 inhibitors: a patent review (2010-2015)

被引：51

作者：

Stazi, Giulia ^{[1
,2
]}

Zwergel, Clemens ^{[1
]}

Valente, Sergio ^{[1
]}

Mai, Antonello ^{[1
,2
]}

机构：

[1] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ple A Moro 5, I-00185 Rome, Italy

[2] Univ Roma La Sapienza, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2016年 / 26卷 / 05期

关键词：

Cancer; epigenetics; lysine specific demethylase 1; viral infections; small molecule inhibitors; HISTONE DEMETHYLASE LSD1; HERPES-SIMPLEX-VIRUS; GENE-EXPRESSION; BREAST-CANCER; CELLS; OXIDASE; BIOLOGY; LATENCY; COMPLEX; LYSINE-SPECIFIC-DEMETHYLASE-1;

D O I：

10.1517/13543776.2016.1165209

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Introduction: Lysine demethylase 1 (LSD1) plays an important role in mediating the expression of genes involved in cancer and non-cancer diseases such as viral infections, cardiovascular and neurodegenerative disorders. It is involved in a number of processes from adipogenesis to cell adhesion to viral latency, regulating several cell pathways related with proliferation, development, and cell cycle control. Numerous chemical entities have been studied in recent years and some of them entered the clinical arena. Areas covered: This review summarizes recent efforts in the drug development of LSD1 inhibitors reported in the patent literature covering the 2010-2015 period, including their potential use as therapeutics in cancerous, neurological, inflammatory, cardiovascular, and viral diseases. Expert opinion: The development of novel potent and selective LSD1 inhibitors is ongoing, in order to improve their potency and selectivity against specific types of cancer or non-cancer diseases. More in-depth studies are required to assess the role of LSD1 inhibitors in the expression of LSD1 target genes, for a better assessment of the biochemistry underlying their efficacy, and to provide evidence for any possible side effects. Furthermore, an interesting therapeutic approach is the use of LSD1 inhibitors in conjunction with other epidrugs to combine their therapeutic potential, leading to innovative, personalized treatments.

引用

页码：565 / 580

页数：16

共 101 条

[1]

Baker J. A., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012107498, 2012107498]

[2]

Baker J.A., 2011, PCT Int. Appl, Patent No. [WO 2011106573 A2 20110901, 2011106573]

[3]

Baker J.A., 2012, PCT Int. Appl, Patent No. [WO 2012072713 A2 20120607, 2012072713]

[4]

Baker JA, 2011, Lysine specific demethylase-1 (LSD1) inhibitors for diseases and disorders associated with hepadnaviridae, Patent No. [WO2011106106A2, 2011106106]

[5] Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity [J].

Bi, Xiangdong ;

Lopez, Christina ;

Bacchi, Cyrus J. ;

Rattendi, Donna ;

Woster, Patrick M. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (12) :3229-3232

[6]

Castro J., 2010, European Patent, Patent No. [2177,502, 2177502]

[7]

Castro-Palomino L.J., 2012, WO Patent, Patent No. [2012/045883 Al, 2012045883, 2012/045883 A1]

[8] Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp [J].

Chau, Charles M. ;

Deng, Zhong ;

Kang, Hyojueng ;

Lieberman, Paul M. .

JOURNAL OF VIROLOGY, 2008, 82 (07) :3428-3437

[9]

Chen Y. K., 2015, Preparation of pyrimidine derivatives as inhibitors of lysine specific demethylase-1, Patent No. [WO2015089192A1, 2015089192]

[10] Crystal structure of human histone lysine-specific demethylase 1 (LSD1) [J].

Chen, Yong ;

Yang, Yuting ;

Wang, Feng ;

Wan, Ke ;

Yamane, Kenichi ;

Zhang, Yi ;

Lei, Ming .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (38) :13956-13961

← 1 2 3 4 5 6 7 8 9 10 →